Article

Medical Crossfire: A Payer and Neurologist Discussion on the Shifting Paradigm of Alzheimer

https://www.pharmacytimes.org/on-demand/an-american-journal-of-managed-care-medical-crossfire-a-payer-and-neurologist-discussion-on-the-shifting-paradigm-of-alzheimers-disease-treatment

https://www.pharmacytimes.org/on-demand/an-american-journal-of-managed-care-medical-crossfire-a-payer-and-neurologist-discussion-on-the-shifting-paradigm-of-alzheimers-disease-treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Saad Z. Usmani, MD, MBA, FACP, FASCO, MSKCC
Related Content
The authors noted their research should be seen as a first step into the exploration of transcriptomics in the 2 diseases. | Image credit: Evrymmnt - stock.adobe.com
August 14th 2025

Study Identifies SSc, SLE Gene Expression Signatures

Jared Kaltwasser
managed care cast banner
August 14th 2025

Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD

Mary Caffrey Skylar Jeremias Joseph Mikhael, MD
The authors recommend incorporating more SoC-specific imagery and case discussions into dermatology curricula, along with a stronger emphasis on biopsy in unclear cases. | Image Credit: Prostock-studio - stock.adobe.com
August 14th 2025

High Rates of Misdiagnosis in Hair, Scalp Disorders Among Patients With Skin of Color

AJMC Contributor
AJMC podcast banner
August 14th 2025

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

Hayden E. Klein Skylar Jeremias Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Older adult holding several pills and glass of water | Image credit: Kotchakorn – stock.adobe.com
August 14th 2025

Polypharmacy Common in Rheumatoid Arthritis, Driving Risk of Serious Drug Interactions

Hayden E. Klein
The long-term data from DELIVER showed meaningful, sustained improvements in functional outcomes and dystrophin expression, as well as a favorable safety profile in patients with Duchenne muscular dystrophy. | Image credit: OlegKachura - stock.adobe.com
August 14th 2025

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

Rose McNulty

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo